Daily Endocrinology Research Analysis
Three high-impact endocrinology papers stand out today: a multicenter RCT shows low-dose vitamin E (300 mg/day) improves biopsy-proven MASH histology; a global OHDSI pharmacoepidemiology analysis suggests a modest NAION risk with semaglutide; and a PRISMA-compliant meta-analysis indicates GLP-1RA cardiovascular benefits may be greater in Asian vs White populations. Together, they advance metabolic therapy, drug safety, and precision cardiometabolic care.
Summary
Three high-impact endocrinology papers stand out today: a multicenter RCT shows low-dose vitamin E (300 mg/day) improves biopsy-proven MASH histology; a global OHDSI pharmacoepidemiology analysis suggests a modest NAION risk with semaglutide; and a PRISMA-compliant meta-analysis indicates GLP-1RA cardiovascular benefits may be greater in Asian vs White populations. Together, they advance metabolic therapy, drug safety, and precision cardiometabolic care.
Research Themes
- Metabolic liver disease therapy optimization (low-dose vitamin E for MASH)
- Drug safety signal evaluation for GLP-1 therapies (semaglutide and NAION)
- Precision cardiometabolic medicine (ethnicity-specific GLP-1RA CV efficacy)
Selected Articles
1. Vitamin E (300 mg) in the treatment of MASH: A multi-center, randomized, double-blind, placebo-controlled study.
In a multicenter double-blind RCT of 124 biopsy-proven MASH patients without diabetes, daily vitamin E 300 mg significantly improved the primary histologic endpoint versus placebo and improved steatosis, lobular inflammation, and fibrosis stages. No treatment-related serious adverse events were identified.
Impact: This trial suggests a lower-dose, widely available antioxidant can deliver meaningful histologic benefits in MASH, addressing an area with few effective pharmacotherapies. It may shift dosing assumptions derived from prior higher-dose vitamin E studies.
Clinical Implications: Vitamin E 300 mg/day could be considered as an adjunct option for biopsy-proven MASH in appropriate non-diabetic adults, while monitoring liver disease and aligning with lifestyle interventions. Broader confirmation and long-term outcomes are needed before widespread uptake.
Key Findings
- Vitamin E 300 mg/day achieved the primary histologic improvement in 29.3% vs 14.1% with placebo (modified ITT).
- Steatosis, lobular inflammation, and fibrosis stages improved significantly in the vitamin E group.
- Twelve serious adverse events occurred but were not deemed treatment-related.
Methodological Strengths
- Multicenter randomized double-blind placebo-controlled design with biopsy-proven MASH.
- Pre-registered trial (ClinicalTrials.gov NCT02962297).
Limitations
- Single-country cohort (Chinese population) may limit generalizability.
- Non-diabetic participants only; applicability to diabetics is unclear.
- Modest sample size (n=124) and histology-based endpoints; long-term clinical outcomes not reported in abstract.
Future Directions: Replicate findings in larger, multiethnic cohorts including patients with diabetes; assess durability of histologic response, non-invasive biomarkers, and hard outcomes (decompensation, HCC, mortality). Dose–response and combination therapy studies are warranted.
The efficacy and safety of a lower dose of vitamin E for metabolic dysfunction-associated steatohepatitis (MASH) treatment are unclear. This multi-center, randomized, double-blind, placebo-controlled study includes 124 non-diabetic participants with biopsy-proven MASH. Participants are randomly assigned to receive oral vitamin E 300 mg or the placebo in a 1:1 ratio. The primary outcome is improvement in hepatic histology. In the modified intention-to-treat population, 29.3% of participants in the vitamin E group achieve the primary outcome compared with 14.1% in the placebo group. Significant improvement in steatosis, lobular inflammation, and fibrosis stages is observed in the vitamin E group. 12 serious adverse events are reported in this trial but are not considered to be related to the treatment. Vitamin E 300 mg daily achieves sound improvements in liver histology in the Chinese population with MASH. This study is registered at ClinicalTrials.gov (NCT02962297).
2. Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy.
Across 14 databases including 37.1 million people with T2D, semaglutide use was associated with a modestly increased NAION risk: SCCS IRR 1.32 (95% CI 1.14–1.54). In active-comparator analyses, risk was not higher than several non-GLP-1 comparators under a sensitive definition, but was higher versus empagliflozin under a more specific definition.
Impact: Given rapid GLP-1 adoption, robust multi-design real-world evidence refining the magnitude of a potential vision-threatening adverse event is clinically critical for informed consent and risk counseling.
Clinical Implications: Clinicians should discuss a small but nonzero NAION risk with semaglutide, particularly in patients with optic nerve vulnerability, while balancing cardiometabolic benefits. Consider ophthalmic symptom vigilance and comparator selection in high-risk individuals.
Key Findings
- NAION incidence among semaglutide users was 14.5 per 100,000 person-years.
- Active-comparator hazard ratios were not different vs non-GLP-1RAs under a sensitive NAION definition; higher risk only vs empagliflozin under a specific definition (HR 2.27, 95% CI 1.16–4.46).
- SCCS meta-analysis showed increased NAION risk during semaglutide exposure (IRR 1.32, 95% CI 1.14–1.54).
Methodological Strengths
- Very large real-world sample across 14 heterogeneous databases with both active-comparator and self-controlled case series designs.
- Propensity score–adjusted Cox models and conditional Poisson SCCS, with random-effects meta-analysis across data sources.
Limitations
- Observational design with reliance on diagnosis codes; residual confounding and misclassification possible.
- Definition-dependent results (sensitive vs specific NAION definitions) complicate effect-size interpretation.
- Exposure timing and ophthalmic phenotype granularity limited without chart validation in all databases.
Future Directions: Prospective ophthalmic safety surveillance and mechanistic studies are needed to define susceptible subgroups, dose–response, and biological plausibility; linkage with imaging/clinical adjudication would refine case definitions.
IMPORTANCE: Semaglutide, a glucagonlike peptide-1 receptor agonist (GLP-1RA), has recently been implicated in cases of nonarteritic anterior ischemic optic neuropathy (NAION), raising safety concerns in the treatment of type 2 diabetes (T2D). OBJECTIVE: To investigate the potential association between semaglutide and NAION in the Observational Health Data Sciences and Informatics (OHDSI) network. DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective study across 14 databases (6 administrative claims and 8 electronic health records). Included were adults with T2D taking semaglutide, other GLP-1RA (dulaglutide, exenatide), or non-GLP-1RA medications (empagliflozin, sitagliptin, glipizide) from December 1, 2017, to December 31, 2023. The incidence proportion and rate of NAION were calculated. Association between semaglutide and NAION was assessed using 2 approaches: an active-comparator cohort design comparing new users of semaglutide with those taking other GLP-1RAs and non-GLP-1RA drugs, and a self-controlled case-series (SCCS) analysis to compare individuals' risks during exposure and nonexposure periods for each drug. The cohort design used propensity score-adjusted Cox proportional hazards models to estimate hazard ratios (HRs). The SCCS used conditional Poisson regression models to estimate incidence rate ratios (IRRs). Network-wide HR and IRR estimates were generated using a random-effects meta-analysis model. EXPOSURES: GLP-1RA and non-GLP-1RAs. MAIN OUTCOMES AND MEASURES: NAION under 2 alternative definitions based on diagnosis codes: one more inclusive and sensitive, the other more restrictive and specific. RESULTS: The study included 37.1 million individuals with T2D, including 810 390 new semaglutide users. Of the 43 620 new users of semaglutide in the Optum's deidentified Clinformatics Data Mart Database, 24 473 (56%) were aged 50 to 69 years, and 26 699 (61%) were female. The incidence rate of NAION was 14.5 per 100 000 person-years among semaglutide users. The HR for NAION among new users of semaglutide was not different compared with that of the non-GLP-1RAs using the sensitive NAION definition-empagliflozin (HR, 1.44; 95% CI, 0.78-2.68; P = .12), sitagliptin (HR, 1.30; 95% CI, 0.56-3.01; P = .27), and glipizide (HR, 1.23; 95% CI, 0.66-2.28; P = .25). The risk was higher only compared with patients taking empagliflozin (HR, 2.27; 95% CI, 1.16-4.46; P = .02) using the specific definition. SCCS analysis of semaglutide exposure showed an increased risk of NAION (meta-analysis IRR, 1.32; 95% CI, 1.14-1.54; P < .001). CONCLUSIONS AND RELEVANCE: Results of this study suggest a modest increase in the risk of NAION among individuals with T2D associated with semaglutide use, smaller than that previously reported, and warranting further investigation into the clinical implications of this association.
3. Comparative Efficacy of Glucagon-Like Peptide 1 Receptor Agonists for Cardiovascular Outcomes in Asian Versus White Populations: Systematic Review and Meta-analysis of Randomized Trials of Populations With or Without Type 2 Diabetes and/or Overweight or Obesity.
A PRISMA-compliant meta-analysis of eight GLP-1RA CVOTs found MACE HRs of 0.69 in Asians vs 0.85 in Whites with a significant interaction (P=0.045), translating to larger absolute risk reduction in Asians (2.9% vs 1.4%). This supports ethnicity-informed decisions for GLP-1RA use in cardiometabolic risk reduction.
Impact: Quantifying ethnicity-specific cardiovascular benefit of GLP-1RAs addresses an equity and precision medicine gap, potentially guiding trial design, labeling, and deployment strategies across populations.
Clinical Implications: For Asian patients at elevated CV risk, GLP-1RAs may confer larger MACE reductions, strengthening the case for earlier initiation. Individualized decisions should still consider baseline risk, accessibility, and patient preferences.
Key Findings
- Across eight CVOTs, GLP-1RAs reduced MACE with HR 0.69 (95% CI 0.58–0.83) in Asians vs 0.85 (0.79–0.91) in Whites.
- Interaction by ethnicity was significant (Pinteraction=0.045).
- Absolute risk reduction was greater in Asians (2.9%, 95% CI 1.5–4.2) than Whites (1.4%, 0.9–1.9).
Methodological Strengths
- PRISMA-compliant systematic review and random-effects meta-analysis of randomized placebo-controlled CVOTs.
- Risk of bias assessed with RoB 2; ethnicity-specific HR extraction.
Limitations
- No individual patient-level data; heterogeneity within "Asian" subgroup cannot be fully resolved.
- Trial-level subgroup analyses risk ecological bias and limited adjustment for confounders.
- Generalizability to routine care may vary by access and background risk differences.
Future Directions: IPD meta-analyses and pragmatic trials stratified by East/South/Southeast Asian subgroups; pharmacogenomic and socioeconomic determinants of response; cost-effectiveness analyses by ethnicity.
BACKGROUND: Cardiovascular outcome trials (CVOTs) suggest glucagon-like peptide 1 receptor agonists (GLP-1RAs) provide greater cardiovascular (CV) benefits in Asian compared with White individuals. PURPOSE: Compare CV efficacy of GLP-1RAs between Asian and White individuals. DATA SOURCES: Systematic review of PubMed and ClinicalTrials.gov (1 January 2015 to 1 November 2024). STUDY SELECTION: Randomized placebo-controlled CVOTs of GLP-1RAs. Risk of bias was assessed (RoB 2). DATA EXTRACTION: Ethnicity-specific hazard ratios (HRs) for major adverse cardiovascular events (MACE). DATA SYNTHESIS: Random-effects meta-analyses per Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines included eight trials (5,909 Asian individuals, 55,855 White individuals). GLP-1RA-associated MACE HR was 0.69 (95% CI 0.58, 0.83) in Asian people and 0.85 (95% CI 0.79, 0.91) in White people (Pinteraction = 0.045). Absolute MACE risk reduction was 2.9% (95% CI 1.5, 4.2) in Asian people versus 1.4% (0.9, 1.9) in White people. LIMITATIONS: Lack of individual patient-level data precluded detailed subclassification of the Asian group. CONCLUSIONS: GLP-1RAs may offer greater MACE reductions in Asian compared with White individuals.